Jacqui Hoffman

机构：Pfizer (United States)

发表论文 22 篇 · 总被引 1165 次 · h-index 11

代表论文

• Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations (2014 · Journal of Medicinal Chemistry · 被引 593)
• Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib (2014 · Journal of Medicinal Chemistry · 被引 118)
• Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer (2012 · Journal of Medicinal Chemistry · 被引 105)
• Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design (2012 · ACS Medicinal Chemistry Letters · 被引 82)
• Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design (2010 · MedChemComm · 被引 73)
• The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 44)